Aclaris Therapeutics (ACRS)
(Delayed Data from NSDQ)
$1.22 USD
-0.02 (-1.61%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $1.28 +0.06 (4.92%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.22 USD
-0.02 (-1.61%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $1.28 +0.06 (4.92%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Zacks News
Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Oct 17, 2019
by Zacks Equity Research
Companies In The News Are: GM, ACRS, MGM, AVD
Aclaris Divests Rhofade to EPI Health for $55M, Shares Up
by Zacks Equity Research
Aclaris (ACRS) divests worldwide rights to its rosacea drug, Rhofade, to privately-held EPI Health as part of its restructuring program.
Top Ranked Momentum Stocks to Buy for October 3rd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 3rd.
Top Ranked Momentum Stocks to Buy for September 27th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, September 27th.
Aclaris Therapeutics, Inc. (ACRS) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Aclaris Therapeutics, Inc. (ACRS).
Aclaris (ACRS) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aclaris (ACRS) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Aclaris (ACRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pacira (PCRX) rides high on both earnings and revenue beat in the second quarter of 2019. Moreover, Exparel drives year-over-year growth.
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 6.49% and 1.65%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) Beats on Earnings in Q2, Lifts 2019 Guidance
by Zacks Equity Research
Zoetis (ZTS) beats on earnings and sales in the second quarter and also raises its 2019 outlook.
Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aclaris Therapeutics Enters Oversold Territory
by Zacks Equity Research
Aclaris Therapeutics has been on a bit of a cold streak lately.
What Makes Aclaris (ACRS) a New Buy Stock
by Zacks Equity Research
Aclaris (ACRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Rigel Initiates Enrollment in Pivotal Blood Disorder Study
by Zacks Equity Research
Rigel (RIGL) enrolls first patient in a pivotal label expansion study evaluating its approved drug, Tavalisse, in patients with antibody autoimmune hemolytic anemia.
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of -13.75% and -1.74%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Aclaris Therapeutics Enters Oversold Territory
by Zacks Equity Research
Aclaris Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Aclaris Therapeutics (ACRS) Enters Oversold Territory
by Zacks Equity Research
Aclaris Therapeutics, Inc. (ACRS) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 15.20% and 3.37%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Aclaris Therapeutics (ACRS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rigel (RIGL) Gets EMA Acceptance for Thrombocytopenia Drug
by Zacks Equity Research
The EMA validates Rigel Pharmaceuticals' (RIGL) marketing application for thrombocytopenia drug, Tavalisse.
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of -6.32% and 33.19%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Aclaris' Alopecia Candidate Gets Fast Track Designation
by Zacks Equity Research
The FDA grants fast track status to Aclaris' (ACRS) JAK-inhibitor, ATI-502, for the treatment of alopecia areata.
Aclaris Stock Up on JAK Inhibitor's Encouraging Activity
by Zacks Equity Research
Aclaris Therapeutics (ACRS) posts positive interim data from a phase II study on its Alopecia Areata candidate, ATI-502.
Humana (HUM) Includes Methodist Healthcare in its Network
by Zacks Equity Research
Humana Inc. (HUM) recently entered into an agreement with Methodist Healthcare to provide better service to its patients.